Remove 2028 Remove Packaging Remove Vaccines
article thumbnail

USP General Chapter —Glass revised

European Pharmaceutical Review

In response to supply chain challenges, including shortages of critical glass vials for products like COVID-19 vaccines and parenteral drugs, the Packaging and Distribution Expert Committee (PD EC) has made a significant revision of United States Pharmacopeia (USP) General Chapter <660>—Glass.

Packaging 105
article thumbnail

STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more

STAT

This calls for celebration with a cup of stimulation, and we are opening a new package of pecan pie for the occasion. In a press release issued ahead of an investor meeting today, the company also said it plans to break even by 2028, when it expects it will reach annual sales of $6 billion. Sound familiar? Have a great day, everyone.

article thumbnail

Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from P-I/II Trial with PDC*lung01

PharmaShots

PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. These new results reinforce our differentiating data package for PDC*lung01.